Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Sunitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 20 Jun 2016 Status changed from active, no longer recruiting to discontinued as PI left institute.
- 01 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by Clinical Trials.gov.